Investor Relations
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jan 05
2021
2021
Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Learn More >
Dec 23
2020
2020
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Learn More >
Dec 15
2020
2020
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
Learn More >
Dec 07
2020
2020
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Learn More >
Dec 06
2020
2020
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Learn More >
Dec 05
2020
2020
Allogene Therapeutics Reports Positive Initial Results from Phase 1 UNIVERSAL Study of ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 62nd American Society of Hematology Annual Meeting
Learn More >
Dec 02
2020
2020
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020
Learn More >
Nov 12
2020
2020
Allogene Therapeutics Announces November and December 2020 Virtual Investor Conference Participation
Learn More >
Nov 04
2020
2020
Allogene Therapeutics Announces Oral Presentation of Initial Results from its Phase 1 Dose Escalation Study of ALLO-715 in Relapsed/Refractory Multiple Myeloma at the 62nd Annual Meeting of the American Society of Hematology
Learn More >
Nov 04
2020
2020